Van Eck Associates Corp Amicus Therapeutics, Inc. Transaction History
Van Eck Associates Corp
- $80.1 Billion
- Q3 2024
A detailed history of Van Eck Associates Corp transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 3,457 shares of FOLD stock, worth $31,182. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,457
Previous 4,564
24.26%
Holding current value
$31,182
Previous $45,000
13.33%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding FOLD
# of Institutions
311Shares Held
314MCall Options Held
516KPut Options Held
833K-
Vanguard Group Inc Valley Forge, PA28.8MShares$260 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY28.1MShares$253 Million7.83% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$220 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA24MShares$216 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY23.2MShares$209 Million3.72% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $2.53B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...